DNAJB8 is a molecular chaperone of the Hsp40 family that functions as an efficient suppressor of protein aggregation and toxicity, particularly for disease-associated polyglutamine proteins 1. The protein operates through a unique mechanism involving oligomerization mediated by an aromatic-rich motif via π-π stacking interactions 2. Its anti-aggregation activity is largely independent of the N-terminal J-domain but requires a C-terminal serine-rich region and C-terminal tail for substrate binding and formation of oligomeric complexes 1. DNAJB8 exhibits regulatory inter-domain interactions between its J-domain and C-terminal domain that control Hsp70 recruitment through a reversible switch mechanism 3. The protein demonstrates disease relevance in multiple contexts: it restricts HIV-1 virion infectivity by facilitating autophagic-lysosomal degradation of viral Vif protein and rescuing APOBEC3G expression 4, and promotes oxaliplatin resistance in colon cancer through interaction with TP53 and upregulation of MDR1 5. Clinically, DNAJB8 is preferentially expressed in colorectal cancer stem-like cells and represents a promising immunotherapy target 67. Its levels in serum small extracellular vesicles may serve as a prognostic biomarker for colon cancer patients 5.